title: Driving allotolerance: CAR-expressing Tregs for tolerance induction in organ and stem cell transplantation.
abstract: Regulatory T cells (Tregs) modulate the function of a variety of immune cells and are critical for maintaining self-tolerance and preventing the development of autoimmune disease. Due to their ability to suppress effector T cells, Tregs have been increasingly explored for clinical use to suppress alloresponses. While this approach has been promising in preclinical models and early clinical trials, widespread clinical use of Tregs has been limited by the low number of these cells in the periphery and the unknown frequency of allo-responsive Tregs. In this issue of the JCI, MacDonald and colleagues transduced human Tregs with a chimeric antigen receptor (CAR) that targets the HLA class I molecule A2. These CAR-expressing T cells were readily activated via CAR stimulation and exerted potent immunosuppressive effects when stimulated in vitro. In a murine model of hematopoietic stem cell transplantation, CAR-modified Tregs were more effective in preventing the development of graft-versus-host disease compared with polyclonal Tregs. The results of this study lay the groundwork for the further evaluation of CAR-expressing Tregs in the prevention or treatment of transplant complications.
authors.forename: Matthias
authors.initials: M
authors.lastname: Edinger
mesh_terms: D000818:Animals; D005260:Female; D015789:HLA-A2 Antigen / Q000276:immunology*; D006801:Humans; D007519:Isoantigens / Q000276:immunology*; D008297:Male; D011948:Receptors, Antigen, T-Cell; D011993:Recombinant Fusion Proteins; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*
chemical_list: D015789:HLA-A2 Antigen; D007519:Isoantigens; D011948:Receptors, Antigen, T-Cell; D011993:Recombinant Fusion Proteins